Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P49711

UPID:
CTCF_HUMAN

ALTERNATIVE NAMES:
11-zinc finger protein; CCCTC-binding factor; CTCFL paralog

ALTERNATIVE UPACC:
P49711; B5MC38; Q53XI7; Q59EL8

BACKGROUND:
The CTCF protein, known for its critical function in transcriptional repression and activation, plays a key role in maintaining chromatin architecture and gene expression. By binding to specific DNA sequences, CTCF regulates a wide array of cellular processes, including cell growth, differentiation, and development. Its ability to modulate gene expression through chromatin insulation and epigenetic mechanisms positions CTCF as a central player in cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Intellectual developmental disorder, autosomal dominant 21, CTCF presents a promising avenue for therapeutic exploration. The intricate role of CTCF in gene regulation and cellular development makes it a compelling target for developing novel treatments for diseases associated with its aberrant function.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.